A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas (Q39975984)

16 September 2017

title

A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas (English)

1 reference

16 September 2017

3

Kristin Bergethon

1 reference

16 September 2017

1

Dora Dias-Santagata

1 reference

16 September 2017

5

A John Iafrate

1 reference

16 September 2017

Quynh Lam

2

1 reference

16 September 2017

Gabrielle M Baker

series ordinal

4

1 reference

16 September 2017

Dinesh Rakheja

series ordinal

6

1 reference

16 September 2017

Mai P Hoang

series ordinal

7

1 reference

16 September 2017

publication date

18 March 2011

1 reference

16 September 2017

1 reference

16 September 2017

volume

24

1 reference

16 September 2017

issue

7

1 reference

16 September 2017

page(s)

974-982

1 reference

Successful adjuvant tamoxifen therapy for estrogen receptor-positive metastasizing sweat gland adenocarcinoma: need for a clinical trial?

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

Tyrosine kinase activating mutations in human malignancies: implications for diagnostic pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

Aneuploidy, but not Ki-67 or EGFR expression, is associated with recurrences in basal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

Decreased survival in EGFR gene amplified vulvar carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

Oncogenic PI3K and its role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

The PIK3CA gene is mutated with high frequency in human breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

Translating insights from the cancer genome into clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

21 January 2018

PIKing the right patient

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

PIK3CA mutations in advanced ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

The p53 tumor suppressor gene in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

p53 mutations in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

p53, the cellular gatekeeper for growth and division

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

Cutaneous hidradenocarcinoma: a clinicopathological, immunohistochemical, and molecular biologic study of 14 cases, including Her2/neu gene expression/amplification, TP53 gene mutation analysis, and t(11;19) translocation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

EGFR and cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

Metastatic hidradenocarcinoma with demonstration of Her-2/neu gene amplification by fluorescence in situ hybridization: potential treatment implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

Clear cell eccrine carcinomas of the skin. A clinicopathologic study of nine patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

7 January 2021

p53 mutations in sweat gland carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

7 January 2021

Genetic changes in sweat gland carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

7 January 2021

A trichilemmal carcinoma arising from a proliferating trichilemmal cyst: the loss of the wild-type p53 is a critical event in malignant transformation

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

7 January 2021

Altered expression of p53 and its regulated proteins in phyllodes tumours of the breast

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

7 January 2021

Epidermal growth factor receptor gene status by fluorescence in situ hybridization in malignant, atypical, and benign hidradenomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.48

7 January 2021

10.1038/MODPATHOL.2011.48

Identifiers

DOI

1 reference

16 September 2017

1 reference